Lilly Asia Ventures is among the participants in a series A round for the lung cancer drug developer that could potentially reach $150m.
US-based oncology drug developer ArriVent Biopharma publicly launched yesterday having secured up to $150m in series A financing from investors including Lilly Asia Ventures, a vehicle for pharmaceutical firm Eli Lilly.
The round is being led by hedge fund manager Hillhouse Capital Group and consists of $90m in funding upfront, with the remaining $60m dependent on certain milestones being reached by the startup.
Healthcare investment firms OrbiMed and Octagon Capital Advisors are also participating in the round, as are financial…
